Skip to search formSkip to main contentSkip to account menu

SU 12662

Known as: SU-12662, SU12662 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

IndolesN-desethyl sunitinibPyrroles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The influence of light sources on sunitinib measurements with photoisomerization.
Sunitinib is an orally administered tyrosine kinase inhibitor. Therapeutic drug monitoring is an important component of the… 
2017
2017
Impact of pharmacokinetics (PK) of sunitinib (SU) and its metabolite SU12662 on clinical outcome and toxicity in metastatic renal cell cancer (mRCC) patients.
506Background: Pharmacological activity of SU is usually attributed to SU and its active metabolite SU12662, known to exhibit… 
Review
2016
Review
2016
An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC).
e12019 Background: SU, an oral multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, FLT3, CSF-1R and RET has activity… 
2016
2016
Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).
274 Background: Angiogenesis is extensively developed in well-differentiated pancreatic neuroendocrine tumors (PNET) where… 
2015
2015
Development, validation and application of the Basel phenotyping cocktail
Personalized therapy is a matter of current discussion in the medical community. It consists of adapting the choice of a drug and… 
2014
2014
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation
AbstractPurpose Sunitinib commonly exhibits dose-limiting dermatological toxicities (DTs) that adversely affect health-related… 
2012
2012
Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a…
A rapid, selective, and sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for the… 
2012
2012
Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations.
In this study we report the pharmacokinetics and severe adverse effects of sunitinib in a woman with a gastrointestinal stromal… 
2011
2011
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.
1Institute of Pharmacy, Clinical Pharmacy, University of Bonn, 2IBMP, Institute for Biomedical and Pharmaceutical Research… 
2006
2006
Pharmacokinetics (PK) and efficacy of sunitinib in patients with metastatic renal cell carcinoma (mRCC).
4531 Background: Sunitinib malate (SU11248) is an oral, multi-targeted tyrosine kinase inhibitor of VEGFR, PDGFR, KIT, FLT3, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)